Document is current
Any future updates will be listed below
-
Authors
Merler, Michele
Agurto, Carla
Peller, Julian
Roitberg, Esteban
Taitz, Alan
Trevisan, Marcos A.
Navar, Indu
Berry, James D.
Fraenkel, Ernest
Ostrow, Lyle W.
Cecchi, Guillermo A.
Norel, Raquel
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 20 April 2025
First Online: 8 May 2025
Competing interests
: Julian Peller, Marcos A. Trevisan and Esteban G. Roitberg are paid consultants to EverythingALS. Alan Taitz was a paid consultant to EverythingALS and his contribution to this work was done while working at EverythingALS. Currently he is an employee of SRI International. James D. Berry has research sup- port from Rapa Therapeutics, MT Pharma of America, ProJenX, Novartis, MDA, ALS Finding a Cure, ALS Association, Association for Frontotemporal Demenia and NINDS. He has been a consultant to Alexion Pharmaceuticals, Amylyx Pharmaceuticals, Biogen, MTPA, Regeneron Pharmaceuticals, Roon, Sanofi and Trace Neuroscience. He is an unpaid scientific advisor to EverythingALS. Indu Navar Bing- ham is the founder of EverythingALS. Lyle W. Ostrow, Ernest Fraenkel, Michele Merler, Carla Agurto, Guillermo Cecchi and Raquel Norel declare no competing interests.
